Full Fed. Circ. Won't Touch MS Drug Patent Royalties Fight
The Federal Circuit said Wednesday it would not reconsider its finding that Biogen MA was the first to invent a particular multiple sclerosis treatment, a decision that blocks Denmark's Forward Pharma...To view the full article, register now.
Already a subscriber? Click here to view full article